Media

Follow our progress and stay up to date with our press releases and media coverage.

Press Releases

GeneVentiv to Attend BIO CEO & Investor Conference

GeneVentiv to Attend BIO CEO & Investor Conference

January 30, 2024 Damon R. Race, President & CEO RALEIGH, NC – GeneVentiv Therapeutics, a pre-clinical gene therapy company focused on blood disorders, today announced it will attend the BIO CEO & Investor Conference, which will be held in New York, NY from...

read more
GeneVentiv to Attend Biotech Showcase

GeneVentiv to Attend Biotech Showcase

November 30, 2023 Damon R. Race, President & CEO RALEIGH, NC – GeneVentiv Therapeutics, a pre-clinical gene therapy company focused on blood disorders, today announced it will attend the Biotech Showcase and BIO Partnering meetings during the J.P. Morgan...

read more
GeneVentiv Therapeutics to Attend BIO Europe Fall 2023

GeneVentiv Therapeutics to Attend BIO Europe Fall 2023

October 10, 2023 Damon R. Race, President & CEO RALEIGH, NC – GeneVentiv Therapeutics, a pre-clinical gene therapy company focused on blood disorders, today announced it will attend BIO Europe Fall 2023, which will be held from November 14-15, 2023.  GeneVentiv...

read more
GeneVentiv to Attend BIO Investor Forum

GeneVentiv to Attend BIO Investor Forum

October 2, 2023 Damon R. Race, President & CEO RALEIGH, NC – GeneVentiv Therapeutics, a pre-clinical gene therapy company focused on blood disorders, today announced it will attend BIO Investor Forum, which will be held in San Francisco, CA from October 17-18,...

read more
GeneVentiv Invited to Present at BioPharm America 2023

GeneVentiv Invited to Present at BioPharm America 2023

August 30, 2023 Damon R. Race, President & CEO RALEIGH, NC – GeneVentiv Therapeutics, a pre-clinical gene therapy company focused on blood diseases and disorders, today announced it has been invited to present at BioPharm AmericaTM, which will be held in Raleigh,...

read more

In the News

UNC-Chapel Hill gene therapy spinout raises $1.4 million

UNC-Chapel Hill gene therapy spinout raises $1.4 million

By Zac Ezzone  –  Staff writer, Triangle Business Journal Sep 1, 2022 A UNC-Chapel Hill spinout developing gene therapies focused on rare blood diseases and disorders has raised $1.4 million to support its efforts. The company, GeneVentiv Therapeutics, raised the...

read more
Universal hope for hemophilia

Universal hope for hemophilia

Universal hope for hemophilia Current hemophilia treatments have limitations for a significant number of patients. That’s why UNC-connected startup GeneVentiv Therapeutics is developing the first universal, single-dose gene therapy for all types of hemophilia,...

read more